Loading
Obesity raises the risk of 13 cancers, and GLP-1 weight-loss drugs are already in routine use for diabetes and obesity. Observational data hint that they cut obesity-related cancers but confounding is severe, so a randomised trial in adults aged 50 to 70 with a BMI of 30 or more should make cancer the primary outcome.
Observational data suggest GLP-1 receptor agonists reduce obesity-related cancer incidence, but confounding is severe. Propose an RCT, or prospective cancer adjudication embedded in ongoing cardiovascular outcome trials, with incident obesity-related cancer as the primary endpoint in adults aged 50-70 with BMI of 30 or more.
One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Maintaining a healthy weight is now established cancer prevention for over a dozen cancer types. For clinicians and policymakers, obesity belongs alongside tobacco and alcohol in prevention strategy. Whether intentional weight loss in adulthood reverses risk is still being studied, including in trials of GLP-1 drugs.
Shares GLP-1 receptor agonists and obesity-related cancer risk, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment.
Shares Link bariatric and GLP-1 registries to cancer registries in every country that has both, GLP-1 receptor agonists and obesity-related cancer risk, Chemoprevention & risk-reducing surgery, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment.
Shares GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer, Link bariatric and GLP-1 registries to cancer registries in every country that has both, GLP-1 receptor agonists and obesity-related cancer risk, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment, Prevention we already have is not deployed, Hepatocellular carcinoma.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.